title: Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during treatment of hypertension with cilnidipine.
abstract: Sixteen adult hypertensive patients of both sexes, classified as having 'medium' (total lipid profile 240-300 mg dl(-1)), and 'high' (total lipid profile >300 mg dl(-1)) baseline values, underwent serum lipids, lipoproteins and plasma fibrinolytic parameters evaluations after 3 months of cilnidipine treatment. Patients with 'medium baseline values' did not have any change in lipids, lipoproteins and fibrinolytic parameters while patients with 'high baseline values' had beneficial lipid and lipoprotein changes [decreases in total cholesterol (TC), triglycerides (TG), very low density lipoprotein-cholesterol (VLDLC) and increases in high density lipoprotein-cholesterol (HDLC), and HDLC/TC ratio] after cilnidipine treatment. Changes in lipids were negatively associated with fibrinolysis for the patients with 'medium baseline values' and positively associated in patients with 'high baseline values' after cilnidipine treatment. Reduction in blood pressure was related to fibrinolysis and reduced risk of coronary heart disease in the patients with 'high baseline values' after cilnidipine therapy. These results show that during cilnidipine treatment, the baseline lipid profile levels of the patients may influence the lipid altering actions as well as the interaction between lipids and fibrinolysis.
authors.affiliation: Department of Physiology and Pathophysiology, Hamamatsu University School of Medicine, 3600 Handa-cho, Hamamatsu-shi, Shizuoka-ken, Japan.
authors.forename: J E
authors.initials: JE
authors.lastname: Ahaneku
authors.forename: K
authors.initials: K
authors.lastname: Sakata
authors.forename: T
authors.initials: T
authors.lastname: Urano
authors.forename: Y
authors.initials: Y
authors.lastname: Takada
authors.forename: A
authors.initials: A
authors.lastname: Takada
mesh_terms: D000368:Aged; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D008055:Lipids; D008074:Lipoproteins; D017395:Plasminogen Activator Inhibitor 1; C065927:cilnidipine; D010959:Tissue Plasminogen Activator